Type V Cas proteins, for example Type V Cas proteins referred to as ZWGD, ZJHK, ZIKV, ZZFT, YYAN, ZZGY, ZKBG, ZZKD, ZXPB, ZPPX, ZXHQ, ZQKH, ZRGM, ZTAE, ZSQQ, ZSYN, ZRBH, ZWPU, ZZQE, and ZRXE Type V Cas proteins; gRNAs for Type V Cas proteins; systems comprising Type V Cas proteins and gRNAs; nucleic acids encoding the Type V Cas proteins, gRNAs and systems; particles comprising the foregoing; pharmaceutical compositions of the foregoing; and uses of the foregoing, for example to alter the genomic DNA of a cell.

Exemplary embodiments described herein include cannabis females that have a potential to form male reproductive parts that may be treated in a manner to affect the gibberellic acid pathway to prevent the formation of male reproductive parts. Additionally, cannabis females may be treated with exogenous compounds (sprays, chemicals, etc.) to reduce the amount of gibberellic acid produced.

Embodiments of the disclosure include compositions and methods for generating RNA nanostructures, particularly in a cell. In particular embodiments, RNA subunits comprising at least one three-way junction and at least one kissing loop are configured such that multiple RNA subunits can polymerize into a specific structure. In particular embodiments, the RNA subunits are configured such that sequence of at least one kissing loop is complementary to sequence of another kissing loop, such as on another RNA subunit, and the summation of multiple RNA subunits having specific individual structures results in a combined polymerized structure of a defined shape. In specific embodiments, an RNA nanostructure generated from methods herein is utilized for an application, such as manufacturing or genetic modifications in a cell.

The present invention relates to the field of increasing genetic diversity in a targeted way. In particular, it relates to the provision of methods and means for targeted sequence diversification using base editors with an expanded mutation spectrum, including the provision of Cas12a diversifying base editing systems, and uses thereof.

The present disclosure relates to methods using CRISPR-Cas13 enzyme, complexed with Influenza A or B crRNA guide RNAs to detect and quantify the presence of Influenza A or B RNA in a sample with enhanced specificity and sensitivity. These methods can be used to diagnose Influenza A or B infection, quantify the concentration of Influenza A or B RNA present in a sample, and identify the presence of different Influenza A subtypes or mutations.

Antimicrobial SbDef1-type peptides and proteins are disclosed along with compositions comprising the SbDef1-type peptides and proteins and transgenic or genetically edited plants or microorganisms that express the SbDef1-type peptides and proteins to inhibit growth of pathogenic microbes. Such SbDef1-type peptides and proteins, compositions, plants, and microorganisms can provide for inhibition of microbial growth.

Provided herein are methods and compositions relating to the use of anti-CD1 10 and anti-CD117 conditioning agents for depletion of endogenous hematopoietic stem cells in a subject, for example. prior to hematopoietic stem cell transplantation. Also provided are cell-based therapy methods and compositions.

Cas protein variants with improved specificity against mismatches between the guide RNA and an RNA target of interest are described. Also described are novel in-silico strategies for designing high specificity Cas variants, a method of detecting a target RNA in a sample with the Cas protein variant, and a kit for detecting a target RNA with the method.

Systems and methods are presented for constructing, training, and utilizing a large contextual gene sequence model that can be provided with variable-length DNA sequence data from larger genomic intervals surrounding annotated genes to predict relative expression across a set of transcriptionally diverse tissues. Additionally, per-nucleotide saliency scores can be extracted from the large contextual gene sequence model, indicating which regions of the DNA sequence surrounding a target gene are associated with regulation of expression of the target gene in various tissue types of an organism. The model described herein surprisingly tolerated averaging across a given embedding of a DNA sequence, and the use of averaging across each embedding allowed the development of a transformer-based model capable of producing a constant set of outputs, indicating the relative expression across a fixed set of tissues, from variable lengths of DNA sequence.

Some embodiments of the method and compositions provided herein relate to methods of preparing cells expressing bispecific T cell engagers (BTCEs), and the use of such cells in certain therapies. In some embodiments, the cells are B cells or B cell precursors.